tirzepatide shortage fda update Update: On December 19th the ruled the tirzepatide was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On tirzepatide news today FDA says

With additional trials ongoing (TRIUMPH-2 and TRIUMPH-3), Retatrutide's anticipated approval could bring state-of-the-art weight management to Flower Mound by 2028

Losing weight can improve many health conditions, including type 2 diabetes, high blood pressure, and sleep apnea

This effect has been noted with GLP-1 receptor agonists as a class and may be further influenced by glucagon receptor agonism

Food sits in your stomach longer, which promotes satiety and reduces calorie intake

Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin

Kavanagh, T